D.B. Root & Company LLC Sells 2,155 Shares of Johnson & Johnson $JNJ

D.B. Root & Company LLC cut its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 41.4% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,046 shares of the company's stock after selling 2,155 shares during the period. D.B. Root & Company LLC's holdings in Johnson & Johnson were worth $465,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of the business. Global Strategic Investment Solutions LLC boosted its holdings in Johnson & Johnson by 3.5% in the second quarter. Global Strategic Investment Solutions LLC now owns 1,925 shares of the company's stock worth $294,000 after purchasing an additional 65 shares in the last quarter. JSF Financial LLC lifted its position in Johnson & Johnson by 2.2% during the 2nd quarter. JSF Financial LLC now owns 2,993 shares of the company's stock worth $457,000 after acquiring an additional 65 shares during the last quarter. Elios Financial Group Inc. lifted its position in Johnson & Johnson by 1.5% during the 1st quarter. Elios Financial Group Inc. now owns 4,496 shares of the company's stock worth $746,000 after acquiring an additional 66 shares during the last quarter. Atlantic Family Wealth LLC lifted its position in Johnson & Johnson by 4.4% during the 1st quarter. Atlantic Family Wealth LLC now owns 1,603 shares of the company's stock worth $266,000 after acquiring an additional 67 shares during the last quarter. Finally, MBA Advisors LLC lifted its position in Johnson & Johnson by 1.2% during the 1st quarter. MBA Advisors LLC now owns 5,553 shares of the company's stock worth $921,000 after acquiring an additional 68 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the firm's stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the sale, the executive vice president owned 178,013 shares of the company's stock, valued at approximately $31,652,491.53. This trade represents a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 0.16% of the company's stock.

Johnson & Johnson Stock Performance

NYSE:JNJ opened at $188.95 on Wednesday. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $189.92. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50. The firm has a market capitalization of $455.06 billion, a PE ratio of 20.21, a price-to-earnings-growth ratio of 2.40 and a beta of 0.40. The firm has a 50-day moving average price of $177.04 and a 200 day moving average price of $163.18.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The firm had revenue of $23.74 billion during the quarter, compared to analyst estimates of $22.85 billion. During the same quarter in the prior year, the business posted $2.82 earnings per share. The company's quarterly revenue was up 5.8% compared to the same quarter last year. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Research analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th were issued a dividend of $1.30 per share. The ex-dividend date of this dividend was Tuesday, August 26th. This represents a $5.20 annualized dividend and a dividend yield of 2.8%. Johnson & Johnson's dividend payout ratio (DPR) is presently 55.61%.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the stock. JPMorgan Chase & Co. boosted their target price on shares of Johnson & Johnson from $185.00 to $200.00 and gave the stock a "neutral" rating in a research report on Tuesday, September 16th. Morgan Stanley boosted their target price on shares of Johnson & Johnson from $171.00 to $176.00 and gave the stock an "equal weight" rating in a research report on Thursday, July 17th. Piper Sandler reissued an "overweight" rating on shares of Johnson & Johnson in a research report on Thursday, July 17th. Weiss Ratings reaffirmed a "hold (c+)" rating on shares of Johnson & Johnson in a research report on Saturday, September 27th. Finally, Citigroup upped their price objective on shares of Johnson & Johnson from $200.00 to $213.00 and gave the company a "buy" rating in a research report on Tuesday. Two analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and nine have issued a Hold rating to the company's stock. According to MarketBeat, Johnson & Johnson currently has an average rating of "Moderate Buy" and an average target price of $189.88.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.